Abstract
A diagnosis of Alzheimer’s disease (AD) is a diagnosis of exclusion. A consideration of current and past medical and psychiatric conditions, surgeries, metabolic abnormalities, and pharmacotherapy is vital to making a diagnosis. Numerous factors can affect cognitive and functional abilities, and it is not unusual for other medical comorbidities to be present in addition to an underlying neurodegenerative process. Although these are rarely solely responsible for cognitive impairment, they may influence cognition adversely. This chapter will discuss recommended practices for the initial assessment of AD, including laboratory, imaging, and other types of diagnostic tests.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Burke A, Hall G, Tariot PN. The clinical problem of neuropsychiatric signs and symptoms in dementia. Continuum (Minneap Minn). 2013;19(2 Dementia):382-396.
Small GW, Rabins PV, Barry PP, et al. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer’s Association, and the American Geriatrics Society. JAMA. 1997;278(16):1363-1371.
American Psychiatric Association. Practice guideline for the treatment of patients with Alzheimer’s disease and other dementias of late life. American Psychiatric Association. Am J Psychiatry. 1997;154(5 suppl):1-39.
Morris JC. Differential diagnosis of Alzheimer’s disease. Clin Geriatr Med. 1994;10:257-276.
Maldonado JR Delirium in the acute care setting: characteristics, diagnosis and treatment. Crit Care Clin. 2008;24:657-722.
Mittal V, Muralee S, Williamson D, et al. Review: delirium in the elderly: a comprehensive review. Am J Alzheimers Dis Other Demen. 2011;26:97-109.
Gauthier S, Reisberg B, Zaudig M, et al. Mild cognitive impairment. Lancet . 2006;367: 1262-1270.
National Institute on Aging, National Institutes of Health. Alzheimer’s disease: unraveling the mystery. NIH publication 08-3782. Published January 2011. www.nia.nih.gov/sites/default/ files/alzheimers_disease_unraveling_the_mystery.pdf. Accessed November 20, 2014.
Lezak MD, Howieson, DB, Loring DW, eds. Neuropsychological Assessment. 5th edition. New York, NY: Oxford University Press; 2012.
Hill-Briggs F, Dial JG, Morere DA, Joyce A. Neuropsychological assessment of persons with physical disability, visual impairment or blindness, and hearing impairment or deafness. Arch Clin Neuropsychol. 2007;22:389-404.
Strauss E, Sherman EMS, Spreen O. A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary. 3rd edition. New York, NY: Oxford University Press: 2006.
Salmon DP, Bondi MW. Neuropsychological assessment of dementia. Annu Rev Psychol. 2009;60:257-282.
Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56:1143-1153.
Fearing MA, Inouye SK. Delirium. In: Blazer DG, Steffens DC, eds. The American Psychiatric Publishing Textbook of Geriatric Psychiatry. Washington, DC: American Psychiatric Publishing; 2009:229-241.
Yaari R, Corey-Bloom J. Alzheimer’s disease. Semin Neurol. 2007;27:32-41.
Hort J, O’Brien JT, Gainotti G, et al; EFNS Scientist Panel on Dementia. EFNS guidelines for the diagnosis and management of Alzheimer’s disease. Eur J Neurol. 2010;17:1236-1248.
Thal LJ, Kantarci K, Reiman EM, et al. The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord. 2006;20:6-15.
Hampel H, Buerger K, Zinkowski R, et al. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch Gen Psychiatry. 2004;61:95-102.
Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. JAMA. 1997;278:1349-1356.
Cruchaga C, Chakraverty S, Mayo K, et al; for the NIA-LOAD/NCRAD Family Study Consortium. Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer’s disease families. PLoS One. 2012;7:e31039.
Wang S-C, Oelze B, Schumacher A. Age-specific epigenetic drift in late-onset Alzheimer’s disease. PLoS One. 2008;3:e2698.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Healthcare
About this chapter
Cite this chapter
Burke, A. et al. (2015). Diagnosing Alzheimer’s Disease. In: Pocket Reference to Alzheimer's Disease Management. Springer Healthcare, Tarporley. https://doi.org/10.1007/978-1-910315-22-4_2
Download citation
DOI: https://doi.org/10.1007/978-1-910315-22-4_2
Published:
Publisher Name: Springer Healthcare, Tarporley
Print ISBN: 978-1-910315-21-7
Online ISBN: 978-1-910315-22-4
eBook Packages: MedicineMedicine (R0)